Pharma must prepare its case meticulously to support its new drug applications.
Putting the who, where and why of real-world studies into context.
Drugs development in 2017 looks very different to how it did 10 years ago, and it’s still evolving.
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
mHealth tech can provide longer-term monitoring for clinical trials.
RWE must become a fundamental accompaniment to traditional RCT data.
UK awards first to introduce a real-world evidence category.
Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
